Seeking Alpha

SciClone Pharma soars, Zadaxin channel inventory build-up resolved

  • SciClone Pharmaceuticals (SCLN) rises 14% premarket on the heels of its Q2 report.
  • CEO Friedhelm Blobel notes that although H1 revenue performance was "disappointing," the Zadaxin channel inventory build-up responsible for sluggish sales growth has been "resolved."
  • FY13 guidance: Zadaxin sales should "rebound" in H2, growing 50% versus H1. FY13 revenues are seen at $135-145M. Full year adjusted EPS should come in between $0.55-0.61.
  • The company also says it will file its previously delayed Q1 10-Q "on or around" August 9 after consulting with the SEC. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: